Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the leading cause of cancer-related death world wide. Early diagnosis and treatment provides the best opportunity for survival, but the prognosis becomes increasingly poor as the cancer starts to spread. Unfortunately, in the majority of cases, by the time symptoms appear and a diagnosis is made, the cancer has already begun to spread.
Oncimmune (LON:ONC) is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body’s natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
